Prostate cancer (PC) is the most common non-cutaneous malignancy in the United States, with an anticipated incidence of 239,000 cases and 29,700 deaths in 2013. Since the advent of prostate-specific antigen (PSA) based screening, approximately 80% of PC cases are now detected because of an elevated PSA level. Although the detection of PC has increased considerably since the introduction of PSA-testing in 1989, randomized screening studies have suggested that PSA screening can lead to both over-diagnosis and overtreatment. Moreover, after a median follow-up of 10 years, the Prostate Cancer Intervention versus Observation Trial demonstrated no differences in prostate-cancer-specific mortality (PCSM) or all-cause mortality among men with low risk disease who were observed versus those treated with a radical prostatectomy (RP). However, given the association of increasing risk of high grade PC with advancing age and the higher likelihood of under-staging by biopsy given increasing prostate gland volume with advancing age, screening for PC in older men who are in excellent health and expected to live at least 10 years should be considered to rule out the possibility that a high-grade PC exists. If low-risk disease is confirmed (ie, PSA ≤10, Gleason score ≤6 and clinical tumor (T) category 1c or 2a), the options of active surveillance versus definitive treatment with either RP or dose-escalated RT should be discussed along with the potential side-effects of each treatment, with the expectation that PSA recurrence-free survival rates approximate 90% at 7 years following treatment.

While PC is the most prevalent non-cutaneous solid malignancy in the United States, CLL/SLL represents the most common leukemia in the Western world, accounting for 30% of all leukemias. CLL/SLL is a chronic lymphoproliferative disorder, heralded by the monoclonal accumulation of mature, functionally-deficient B-lymphocytes. The majority of patients present with a lymphocytosis of >5000 B-lymphocytes/ul, diagnostic of CLL. A smaller number of patients present with lymphadenopathy caused by cells with an identical immunophenotype as CLL, but with <5,000 B-cells/ul, diagnostic of SLL. Patients with either SLL or CLL in the absence of splenomegaly or cytopenias are considered to have early stage disease. FISH can provide important prognostic information. Trisomy-12 occurs in ~16% of patients and is generally a favorable indicator.

The management of early stage SLL is dependent upon the presence of disease-related symptoms, threatened end-organ dysfunction or bulky disease. Close monitoring remains an option in the absence of these indications, although locoregional radiotherapy can be curative in early stage disease.
CASE SUMMARY
A 79-year-old male presented with a prostate-specific antigen (PSA) that rose from 2.5 to 7.2 ng/mL over 22 years, prompting biopsies, which showed chronic prostatitis. In 2013, a digital rectal examination (DRE) demonstrated an enlarged prostate, and the PSA increased from 7.2 ng/mL to 9.2 ng/mL over 14 months without confounders. This prompted rebiopsy of a prostate gland, which measured 148 cc on transrectal ultrasound (PSA density = 0.06 ng/mL/cc), revealing prostatic adenocarcinoma, Gleason score 3 + 3 = 6 in one of six right-sided prostate needle biopsy (PNB) cores involving <5% of the specimen; and Gleason score 3 + 3 = 6 in two of six left-sided PNB cores involving 10% and 15% of these cores (Figure 1). The remainder of the physical examination revealed no lymphadenopathy in Waldeyer’s ring or peripherally, and there was no splenomegaly. The history did not elicit any B symptoms or significant lower urinary tract symptoms.

IMAGING FINDINGS
Given the rapid rise in PSA (PSA velocity = 1.7 ng/mL/year), staging with an endorectal and pelvic MRI was obtained showing enlarged pelvic sidewall lymph nodes bilaterally. Percutaneous biopsy of a right-sided lymph node revealed an atypical lymphocytic population. By immunohistochemistry and flow cytometry, this population expressed B-cell markers CD19 and CD20, co-expressed CD5 and CD23, demonstrated monotypic expression of surface immunoglobulin lambda, and lacked cyclin D1 expression, consistent with the histologic diagnosis of chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) (Figure 1). Although the complete blood count was unremarkable, interphase fluorescence in situ hybridization (FISH) of

peripheral blood showed trisomy 12 in 6% of cells, characteristic of CLL/SLL. CT of the chest, abdomen, and pelvis revealed no distant foci of disease. The patient was otherwise in excellent health with a history of gastroesophageal reflux disease and hypercholesterolemia. His medications included atorvastatin, omeprazole, and tamsulosin.

In the setting of anatomically-adjacent synchronous primary tumors, multidisciplinary discussion concluded that concurrent definitive treatment of both lesions was the optimal approach given the patient’s desire to undergo treatment rather than surveillance, and his excellent underlying health with a remaining life expectancy (RLE) exceeding 10 years (RLE = 8.62 years, based on social security administration tables. +50% based on clinical indicators to suggest top quartile of health). To that end, image-guided radiotherapy (IGRT) was employed to encompass the prostate along with the bilateral internal iliac lymph nodes to a dose of 3,960 cGy in 22 fractions (Figure 2). Upon reaching this curative dose for stage II SLL (highest local control rates for SLL are approached at ~40Gy), the treatment volume was reduced and an additional 3,600 cGy was delivered in 20 fractions to the prostate alone (Figure 2) for a total definitive dose of 7,560 cGy to the prostate gland (Figure 3). The patient completed definitive therapy without significant bowel or bladder toxicity. He did not report diarrhea, nausea, weight loss, or change in bowel habits. Tamsulosin was increased from 0.4 mg daily to 0.4 mg twice per day to manage increased nocturia attributed to radiation urethritis, although this resolved within 2 weeks following the completion of treatment, and after tamsulosin was discontinued.

**DISCUSSION**

Although patients with early-stage SLL are often observed, involved-field radiotherapy alone without systemic treatment may be pursued with curative intent. This approach is based on data extrapolated from the management of other indolent NHLs along with retrospective series showing the efficacy of radiation alone. In one such study, 54 patients with SLL were treated with variable regimens of chemotherapy and radiotherapy. Among 14 patients with early stage disease who received radiation without systemic treatment, 10-year freedom from recurrence (FFR) was 62% to 80%, demonstrating a prolonged endpoint and potential “cure” for the majority of these patients. Consensus recommendations for localized SLL include involved-site radiotherapy to a dose of 24 Gy to 30 Gy targeting the involved lymph nodes.

The management of multiple primary cancers has long represented a clinical challenge with few data to guide therapy. Synchronous primary tumors have been described with varying frequency and are generally thought to arise from genetic predisposition (eg, Li-Fraumeni syndrome, BRCA1/2, etc.), environmental exposures (eg, tobacco, radiation, etc.), adverse treatment effects (eg, carcinogenic chemotherapy or radiotherapy), or combinations of these factors.
Patients with CLL/SLL may be particularly susceptible to second malignancies, potentially due to impaired immune surveillance of tumor cells. After an assessment of competing risks, initial therapy is typically directed at the most life-threatening condition with the goal of prolonging disease free and overall survival while attempting to minimize the impact of therapy on quality of life. Typically, due to the cumulative toxicity of combining differing therapies for distinct cancers, the treatment approach necessitates focusing on one malignancy while delaying treatment for the other. Occasionally, however, synchronous tumors share common treatment strategies and are amenable to concurrent definitive therapy, as in this report. In addition, if the RLE is long in comparison to the natural history of symptomatic progression of the cancer, treatment should be offered. Therefore, given the absence of competing risks to shorten life expectancy in the case presented, and the favorable toxicity profile of treating the prostate and bilateral internal iliac lymph-nodal chains with IGRT (ie, 7% risk of acute Grade 2 rectal or bladder toxicity, with no report of Grade 3 or higher toxicity), unimodality treatment with IGRT was designed and implemented simultaneously for both cancers. Moreover, the anatomic proximity of the two cancers allowed for both to be encompassed within a single radiation treatment field. Evidence-based dose-constraints for the rectum were achieved, including a V75 of 7.5% and V70 of 11.5% (per guidelines V75 ≤15% and V70 ≤20%) [16]. Similarly, the small bowel was not within the treatment field and a tolerance of V45 ≤195cc was achieved. The treatment was well tolerated without clinically-significant bowel or bladder toxicity.

The routine post-treatment monitoring for low-risk PC consists of a DRE and PSA testing every 6 months for 5 years and annually thereafter. The routine follow-up care for localized SLL includes follow-up at semi-annual visits for disease-related symptoms (fatigue, night sweats, unexplained weight loss, etc.) along with hematologic surveillance for leukocytosis, anemia, or thrombocytopenia. One challenge with post-therapy follow-up is that survivors of certain cancers may receive lower quality care for non-oncologic competing risks than matched controls without a prior

**FIGURE 3.** A dose-volume histogram (DVH) outlines the dose received by target tissues and organs at risk. PTV1 (red) refers to the first course of treatment encompassing both the prostate and the pelvic lymph nodes, prescribed to a dose of 3960 cGy. PTV2 (yellow) refers to the subsequent cone-down volume, delivering an additional 3600 cGy to the prostate.
cancer diagnosis. Specifically, survivors of PC were found to be less likely than controls to receive quality acute care for non-cancer-related illnesses (odds ratio 0.75). While further studies are needed to determine why certain cancer survivors receive suboptimal care, there is clearly a need for greater vigilance when it comes to the health care of this population; otherwise, the benefit gained in cancer-specific survival via curative treatment may not translate into an overall survival benefit due to inter-current death from a neglected competing risk.

**CONCLUSION**

Thus, a case is presented of an elderly yet healthy man with synchronous cancers amenable to curative treatment with a single therapeutic modality and minimal risk of toxicity, affording ~60% chance of long-term cancer control. When selecting patients of advanced age for curative therapy of synchronous cancers where multiple treatments may be indicated, the patient’s wishes should be considered following appropriate education about the risks and benefits of treatment(s), discussion of competing risks and RLE, and review of appropriate follow-up care. These considerations should be aimed at maximizing cancer control while minimizing the impact of treatment on quality of life.

**REFERENCES**